Skip to main content

Table 1 Patient characteristics and observed pathological complete response (pCR)

From: Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients

Characteristics

Number of patients

Number of pCR (%)

Chi-squared test P value

Multivariate P value

Age

  

0.564

NS

  < 40

60

23 (38.3)

  

 40–59

194

66 (34.0)

  

 60+

49

14 (28.6)

  

Menopausal status

  

0.817

NS

 Pre

159

55 (34.6)

  

 Post

144

48 (33.3)

  

Tumor size at baseline

  

0.026

0.030

 T2

150

62 (41.3)

  

 T3

100

28 (28.0)

  

 T4

53

13 (24.5)

  

Node status at baseline

  

0.917

NS

 -

52

18 (34.6)

  

 +

251

85 (33.9)

  

Histology at baseline

  

0.263

NS

 Invasive ductal carcinoma

224

82 (36.6)

  

 Invasive (mixed) carcinoma

62

17 (27.4)

  

 Others

17

4 (23.5)

  

Ki-67 expression at baseline

  

< 0.001

0.001

  < 20%

107

22 (20.6)

  

  ≥ 20%

196

81 (41.3)

  

sMMP-9 at baseline (ng/ml)

  

0.519

NS*

 Low (< 505.5)

101

34 (33.7)

  

 Intermediate (505.5–712.8)

100

38 (38.0)

  

 High (> 712.8)

102

31 (30.4)

  

sMMP-9 at surgery (ng/ml)

  

0.020

0.043*

 Low (< 423.2)

100

42 (42.0)

  

 Intermediate (423.2–612.3)

102

37 (36.3)

  

 High (> 612.3)

101

24 (23.8)

  

sMMP-9 decrease (ng/ml)

  

< 0.001

0.003*

 Low (< 28.3)

100

24 (24.0)

  

 Intermediate (28.3–143.8)

101

29 (28.7)

  

 High (> 143.8)

102

50 (49.0)

  

Clinical response

  

0.172

NS

 CR/PR

102

40 (39.2)

  

 SD/PD

201

63 (31.3)

  
  1. *sMMP-9 was studied in the multivariate analysis as linearly variable